A.R. Filippi , M. R. García Campelo , J-B. Paoli , D. Kowalski , C. Bennati , P. Borghetti , D. Cortinovis , A. Delmonte , C. Genova , R. Mroz , S. Nawrocki , I. Toledano , G. Tonini , F. Agustoni , G. Wetherill , I. Diaz Perez , N. Georgoulia , R. Dziadziuszko
{"title":"66MO Durvalumab在无法切除的不适合化疗(CT)的III期NSCLC患者(pts)放疗后(RT): II期DUART研究的最终分析","authors":"A.R. Filippi , M. R. García Campelo , J-B. Paoli , D. Kowalski , C. Bennati , P. Borghetti , D. Cortinovis , A. Delmonte , C. Genova , R. Mroz , S. Nawrocki , I. Toledano , G. Tonini , F. Agustoni , G. Wetherill , I. Diaz Perez , N. Georgoulia , R. Dziadziuszko","doi":"10.1016/j.iotech.2024.100809","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100809"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"66MO Durvalumab after radiotherapy (RT) in patients (pts) with unresectable stage III NSCLC ineligible for chemotherapy (CT): Final analysis of the phase II DUART study\",\"authors\":\"A.R. Filippi , M. R. García Campelo , J-B. Paoli , D. Kowalski , C. Bennati , P. Borghetti , D. Cortinovis , A. Delmonte , C. Genova , R. Mroz , S. Nawrocki , I. Toledano , G. Tonini , F. Agustoni , G. Wetherill , I. Diaz Perez , N. Georgoulia , R. Dziadziuszko\",\"doi\":\"10.1016/j.iotech.2024.100809\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":73352,\"journal\":{\"name\":\"Immuno-oncology technology\",\"volume\":\"24 \",\"pages\":\"Article 100809\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immuno-oncology technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590018824001060\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-oncology technology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590018824001060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
66MO Durvalumab after radiotherapy (RT) in patients (pts) with unresectable stage III NSCLC ineligible for chemotherapy (CT): Final analysis of the phase II DUART study